• 
• 

• 
• 
• 
• 
• 
• 

UNIVERSITY OF CHICAGO: 

IRB Approved: 

NCIC CTG MA.20 (RTOG Endorsed Study): A Phase III Study of Regional Radiation Therapy in Early Breast Cancer 

PI – Steven Chmura, MD, PhD

RTOG 0424: A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High Risk Low-Grade Gliomas

PI – Steven Chmura, MD, PhD

 

RTOG 0525: Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma

PI – Steven Chmura, MD, PhD

 

RTOG 0247: Randomized Phase II Trial of Neoadjuvant Combined Modality Therapy for Locally Advanced Rectal Cancer

PI – Ashesh Jani, MD 

 

In IRB Review: 

RTOG 0415: A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer      

PI – Ashesh Jani, MD

 

 

UNIVERSITY OF ILLINOIS AT CHICAGO (UIC): 

Approved by Cancer Center Protocol Review Committee, but not yet submitted to IRB:  

RTOG 0424: A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High Risk Low-Grade Gliomas

PI – Howard Halpern, MD, PhD